Levetiracetam Tablet, Film Coated
Product Images NDC 68788-7884

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68788-7884). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam Tablets 250mg (Leveannora250mg30scount)

Levetiracetam Tablets 250 mg film-coated oral tablets label. The label includes dosage strength, generic name, and manufacturer details (Camber Pharmaceuticals, Inc.). It has directions for use in English and Spanish, storage instructions, and a caution about federal law prohibiting drug transfer. The label design features yellow blocks with black text and a barcode.*

FDA Label Image

Levecamberlogo1 (Levecamberlogo1)

FDA Label Image

Levefig1 (Levefig1)

A bar chart comparing the percentage of patients across three groups: placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis represents the percentage of patients, showing higher percentages in the Levetiracetam groups compared to placebo, with values approximately 7.4% for placebo, 37.1% for Levetiracetam 1000 mg/day, and 39.6% for Levetiracetam 3000 mg/day.*

FDA Label Image

Levefig2 (Levefig2)

A bar graph showing the percentage of patients experiencing an outcome across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The percentages increase from placebo (6.3%) to Levetiracetam 1000 mg/day (20.8%) and highest in Levetiracetam 2000 mg/day (35.2%).*

FDA Label Image

Levefig3 (Levefig3)

A bar chart comparing the percentage of patients between two groups: Placebo (N=104) at 14.4% and Levetiracetam 3000 mg/day (N=180) at 39.4%. The vertical axis shows the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Levefig4 (Levefig4)

A bar graph comparing percentage recovery of patients between placebo and Levetiracetam (250 mg). The graph shows approximately 19.6% recovery for placebo and 44.6% for Levetiracetam, with sample sizes of 87 and 101 respectively.*

FDA Label Image

Levefig5 (Levefig5)

A bar chart comparing the percentage of subjects classified as responders between placebo and Levetiracetam groups. The chart shows approximately 45.2% response for placebo (N=64) and 72.2% for Levetiracetam (N=79), illustrating higher efficacy in the Levetiracetam group.*

FDA Label Image

Levefig6 (Levefig6)

A bar chart comparing the percent reduction between Placebo (N=56) and Levetiracetam (N=79). The Placebo group shows a 45.2% reduction, while the Levetiracetam group shows a 72.2% reduction.*

FDA Label Image

Levestructure (Levestructure)

Chemical structure of levetiracetam, showing its molecular framework including a pyrrolidone ring and associated substituents.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.